|
|
||||||||
,1
* Division of Cancer Genomics and Proteomics, Ontario Cancer Institute, University Health Network, University of Toronto, Toronto, Canada; and
Renal Division and Department of Medicine, St. Michaels Hospital and University of Toronto, Toronto, Canada
1To whom requests for reprints should be addressed at University of Toronto, Medical Sciences Building, Room 7358, 1 Kings College Circle, Toronto, ON M5S 1A8. E-mail: p.marsden{at}utoronto.ca
Abstract
Endothelin-1 (ET-1) is a potent endothelial-derived vasocon-strictor and cellular mitogen. Perturbations in ET-1 levels have been observed in a number of cardiovascular and renal disorders. Steady-state ET-1 mRNA expression is regulated in the vascular endothelium by an inducible promoter and a constitutively short mRNA half-life. Recent studies have identified mRNA stabilization as a pathophysiologically relevant mechanism of ET-1 induction in vascular endothelial cells. However, mechanistic studies on posttranscriptional pathways in physiologically relevant postconfluent primary endothelial cell monolayers have remained challenging because of endothelial resistance to DNA-based gene transfer and expression. To overcome these challenges, we developed an RNA transfection method to study ET-1 posttranscriptional regulation. Reporter transcripts transfected into either preconfluent or postconfluent primary endothelial cells were rapidly and robustly expressed. RNA transfection reconstituted poly(A)-taildependent protein expression and ET-1 3'-UTRdependent mRNA destabilization, suggesting that the transfected RNA accessed endothelial cell posttranscriptional pathways. Because RNA transfection uncouples transcription from expression, the influence of the ET-1 3'-UTR on posttranscriptional expression kinetics could also be monitored. Taken together, our results suggest that RNA transfection is a versatile tool to investigate ET-1 posttranscriptional regulation in endothelial cell culture models.
Key Words: 3'-untranslated region endothelin endothelium gene regulation mRNA stability RNA transfection
Introduction
Endothelin-1 (ET-1) is a potent endothelial-derived vasoconstrictor and cellular mitogen (1). In vitro and in vivo studies have implicated aberrant ET-1 expression as a marker of endothelial dysfunction, inflammatory vascular disease, and cardiac and vascular remodeling (2). ET-1 expression is regulated by an inducible promoter and a constitutively short mRNA half-life (30 min), enabling ET-1 mRNA and protein expression to mirror acute changes in transcriptional activity (3, 4).
Recent studies have identified a number of pathophysiologic cell stimuli that stabilize the ET-1 mRNA (47). For example, we previously observed that verotoxin, a type-A:B5 toxin implicated in hemorrhagic colitis and hemolytic uremic syndrome, enhances endothelial cell ET-1 mRNA and protein expression through a mechanism of mRNA stabilization (5). Despite these advances, mRNA stabilization remains a poorly understood pathway of ET-1 biosynthesis. Moreover, mechanisms operative in the control of mRNA stability and translation in the vascular endothelium, in health and in disease, are poorly understood. In this regard, studies with the ET-1 mRNA offer a relevant model to dissect these pathways.
Mechanistic studies of a specific genes mRNA typically involve the genetic uncoupling of mRNA expression from native transcriptional activity. For example, wild-type or mutant transcripts can be ectopically expressed from mammalian expression plasmids bearing constitutively active promoters and mRNA processing signals. Our laboratory and other laboratories have successfully used this approach to identify functionally important regions necessary for rapid ET-1 mRNA turnover (4, 8). Using transient transfection of expression plasmids into primary bovine aortic endothelial cells (BAECs), we localized an mRNA destabilizing activity to two regions of the ET-1 3'-UTR, termed DE1 and DE2 (destabilizing elements 1 and 2) (4). Although this method facilitates robust mechanistic studies in subconfluent BAEC and human nonendothelial cell lines, studies in postconfluent cell monolayers or transfection-resistant human primary endothelial cells remains challenging, owing in part to low transfection efficiencies. In addition, there is considerable difficulty in developing stable cell lines from cultured human umbilical vein endothelial cells (HUVECs) because of senescence and phenotypic loss beyond early passages (9). To overcome these challenges, we developed and optimized an RNA-based transfection methodology to study ET-1 posttranscriptional regulation in confluent endothelial cell monolayers. We present evidence that this method recapitulates the ET-1 3'-UTR destabilizing activity previously observed using transient or stable plasmid DNAbased RNA expression methods (4). RNA transfection may therefore be a versatile tool to investigate ET-1 posttranscriptional gene regulation.
Materials and Methods
Cell Culture.
All cell culture reagents were obtained from Invitrogen unless otherwise indicated. Primary BAECs and HUVECs were isolated and cultured as previously described (4, 10). BAECs and HUVECs were used at passages 37. Human cervical epithelial carcinoma (HeLa) cells were obtained from ATCC (Manassas, VA) and cultured as previously described (4, 10).
Plasmids.
Restriction enzymes, DNA modifying enzymes, and Taq polymerase were obtained from New England Biolabs (Beverly, MA) and Invitrogen (Burlington, Canada). All plasmids were generated using standard recombinant DNA methodologies and sequenced with an ABI Prism 377 DNA sequencer (ABI, Foster City, CA). In vitro transcribed reporter transcripts were synthesized from either pLuc-Ctrl or pLuc-Ctrl-A60 containing a bacteriophage T7 promoter directing the transcription of a firefly luciferase reporter RNA with a 0 or 60 nt poly(A) tail. An EcoRI site immediately downstream of firefly luciferase allowed for insertion of sequences within the 3'-UTR (see Fig. 1
). Synthesis of pLuc-Ctrl was performed as described elsewhere (4). pLuc-Ctrl-A60 was synthesized by HindIII/XhoI excision of the poly(A)-containing luciferase from pSP-Luc+-A60 (11) and into identical sites within pcDNA3 (Invitrogen). Wild-type ET-1 3'-UTRs were excised from host plasmids (4) by partial EcoRI digestion followed by ligation into the EcoRI site of pLuc-Ctrl-A60. pRSV-ß-gal-A60 was used to synthesize ß-gal-A60 transcripts, as previously described (11).
|
Transfections.
Unless stated otherwise, 1 x 105 BAECs were seeded in gelatin-coated 60-mm dishes, cultured to confluence for 48 hrs, transfected with equimolar amounts of capped RNAs (0.35 µg/kb), 1.5 µg of capped ß-gal-A60 RNA (transfection efficiency control), and sufficient total cellular BAEC RNA to a total of 3 µg transfected RNA per plate. Transfections were performed with Lipofectin Reagent (Invitrogen) according to the manufacturers protocol at a lipid:RNA mass ratio of 2:1 for 6 hrs, unless indicated otherwise. Total cellular protein was extracted in triplicate and measured for luciferase activity (test transcripts) (10), ß-galactosidase activity (cotransfected efficiency control) (11), and protein concentration (12). Total cellular RNA was extracted in pooled duplicates and analyzed by Northern blot, as previously described (4). RNA transfection experiments were repeated two to five times in independent BAEC or HUVEC clones with at least two independent lots of in vitro synthesized RNA.
Data Analysis.
Data points represent the mean ± SEM of a representative or multiple independent experiments. Statistically significant differences represent P < 0.05 calculated by either the unpaired Students t test or analysis of variance (Dunnet or Bonferroni posttests; GraphPad Software Inc., San Diego, CA).
Results
Development and Optimization of RNA Transfection Methods.
We developed an RNA transfection system to study posttranscriptional gene regulation in postconfluent endothelial cell cultures. Plasmids were engineered for in vitro transcription of capped luciferase reporter transcripts with either a 0 or 60 nt poly(A) tail and control or ET-1 3'-UTRs (Fig. 1
). Luciferase reporter transcripts were efficiently transcribed in vitro and robustly expressed in transfected confluent BAECs (Fig. 2
). Transcripts with a poly(A) tail 60 nt in length exhibited protein expression that was 50-fold greater than that for transcripts without a poly(A) tail, whereas steady-state RNA levels were not different, at least as measured 6 hrs after transfection (Fig. 2B and C
). This finding suggests RNA stability was not affected and that reporter transcripts were translationally enhanced, which is consistent with a previously established role for poly(A) tails in enhancing mRNA translational efficiency (13, 14).
|
|
|
Preconfluent and postconfluent primary endothelial cell cultures have markedly different phenotypes and gene expression profiles (3, 15, 16). Postconfluent endothelial cells (BAECs or HUVECs) attain a quiescent and pseudodifferentiated phenotype that resembles healthy vascular endothelium, whereas proliferating preconfluent endothelial cells resemble an activated endothelium typically seen in the presence of inflammation or vascular remodeling. These differences in phenotype are also represented by changes in gene expression. For example, postconfluent endothelial cells feature low-level ET-1 transcription and a stable eNOS mRNA (half-life, >24 hrs) whereas proliferating preconfluent endothelial cells feature activated ET-1 transcription and an unstable eNOS mRNA (half-life, <4 hrs) (3, 15).
In this study, we describe the development and optimization of an RNA transfection method to study posttranscriptional regulation in postconfluent primary endothelial cells, namely BAECs and HUVECs. DNA transfection and expression requires that plasmids access cellular nuclei for transcription; this process primarily occurs in proliferating cells (17). However, postconfluent endothelial cell monolayers have a very small percentage of proliferating cells (15), resulting in significantly decreased transfection efficiency. In contrast, RNA transfection bypasses the requirement for transcription and enables direct transcript expression in the cytoplasm.
We investigated the RNA destabilizing activity of the ET-1 3'-UTR and found that RNA transfection recapitulates the posttranscriptional activity previously reported using DNA-based transfection methods in BAECs, HUVECs, and HeLa cells (Fig. 3
; Refs. 4, 8). We did not observe differences in ET-1 3'-UTR activity in preconfluent versus postconfluent BAECs, suggesting that cell density does not regulate ET-1 3'-UTR activity under basal conditions. These findings recapitulate our earlier studies involving DNA-based reporter methods to determine endogenous ET-1 expression in BAEC (data not shown) (4). These findings are also consistent with results of studies showing that increased ET-1 expression in proliferating vascular endothelial cells is primarily due to increased ET-1 mRNA transcription, rather than mRNA stability (15). However, we cannot exclude the possibility that endothelial cell density or expression does not influence ET-1 mRNA stability in pathophysiologic settings in vitro or in vivo. RNA transfection may therefore enable future studies on ET-1 mRNA stability in endothelial injury models requiring postconfluent endothelial cell monolayers.
An important feature of our system is its sensitivity to poly(A) tail length (Fig. 2
). Translational efficiency and mRNA stability are significantly influenced by the presence or absence of a poly(A) tail, because of the interaction of poly(A) binding protein, mRNA cap-binding proteins, and in some cases, functional 3'-UTR cis-elements (13, 18). It is now appreciated that 3'-UTR regulated poly(A) tail length plays a critical role in pathophysiologic gene regulation (1921). Therefore, synthetic control over poly(A) tail lengths could be an important tool for uncovering poly(A) tailregulated pathways in health and disease.
A significant aspect of ET-1 biology is the transcriptional induction of ET-1 and the subsequent rate, magnitude, and persistence of ET-1 biosynthesis. Our kinetic studies (Fig. 4
) recapitulate kinetic studies by others that used a DNA-based ET-1 promoter/3'-UTR reporter system (8). Together, results of these studies suggest the ET-1 3'-UTR may limit ET-1 expression, thereby attenuating the potentially harmful effects of excessive ET-1 production (1).
Our study defines RNA transfection as a versatile tool for investigating ET-1 posttranscriptional regulation in physiologically relevant postconfluent primary endothelial cell monolayers. This method may also be extended to the study of ET-1 mRNA stability in other complex cell culture models and in ex vivo/in vivo vascular models. The development of robust tools to understand gene expression in primary vascular endothelial cells will facilitate the discovery of gene regulatory networks that contribute to the health and disease of the vascular endothelium.
Footnotes
This research is supported by a grant from the Kidney Foundation of Canada. P.A.M. is a Heart and Stroke Foundation of Canada Career Investigator. I.A.M. is the recipient of a Canadian Institute of Health Research/Heart & Stroke Foundation of Canada Doctoral Research Award.
Received for publication September 30, 2005. Accepted for publication December 16, 2005.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |